U.S. markets closed
  • S&P 500

    3,941.26
    -57.58 (-1.44%)
     
  • Dow 30

    33,596.34
    -350.76 (-1.03%)
     
  • Nasdaq

    11,014.89
    -225.05 (-2.00%)
     
  • Russell 2000

    1,812.58
    -27.65 (-1.50%)
     
  • Crude Oil

    74.41
    -2.52 (-3.28%)
     
  • Gold

    1,783.40
    +2.10 (+0.12%)
     
  • Silver

    22.35
    -0.06 (-0.28%)
     
  • EUR/USD

    1.0469
    -0.0029 (-0.27%)
     
  • 10-Yr Bond

    3.5130
    -0.0860 (-2.39%)
     
  • GBP/USD

    1.2132
    -0.0062 (-0.51%)
     
  • USD/JPY

    137.0510
    +0.3660 (+0.27%)
     
  • BTC-USD

    16,997.93
    +16.70 (+0.10%)
     
  • CMC Crypto 200

    400.49
    -1.32 (-0.33%)
     
  • FTSE 100

    7,521.39
    -46.15 (-0.61%)
     
  • Nikkei 225

    27,885.87
    +65.47 (+0.24%)
     

UPDATE 1-Pfizer expects updated COVID-19 vaccine data for kids under 5 by April

(Adds background, details on 5-11 year olds)

NEW YORK, Jan 5 (Reuters) - Pfizer Inc expects the latest results from a clinical trial for kids under the age of 5 of the COVID-19 vaccine it developed with Germany's BioNTech SE by April, a top company scientist said on Wednesday.

"The study has been amended to give a third dose to everybody who's less than five at least eight weeks after their last vaccination," Dr. Alejandra Gurtman, a Pfizer vaccine researcher said at a meeting of the U.S. Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices (ACIP). She said the company aims to have data for the age group by the end of March or the beginning of April.

In December, Pfizer said it was changing the design of the trial because children between the ages of 2 and 4 who were given two 3-microgram doses of the vaccine did not have the same immune response that a larger dose of the vaccine generated in older children.

Gurtman also said the company was studying a third dose of its vaccine in children ages 5 to 11, six months after their second dose.

The Pfizer-BioNTech vaccine is authorized in the United States for people age 5 and older. On Wednesday, ACIP backed booster shots of the vaccine for ages 12 to 15.

(Reporting by Michael Erman; Editing by Leslie Adler and Bill Berkrot)